Internal Medicine, Rheumatology · Lafayette, LA
NPI
1336137215
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
913 S College Rd, Suite 110
Lafayette, LA, 70503
Phone (337) 237-5008
Groups this clinician bills Medicare through
Medicare paid, 2024
$949K
115,355 services
Medicare patients, 2024
587
Average age 73
Drug cost, 2024
$961K
3,374 prescriptions
Company payments, 2025
$24K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ladislas Lazaro IV was code J1602 (injection, golimumab, 1 mg, for intravenous use), 33,846 times for 41 patients. In total Ladislas Lazaro IV billed 115,355 services in 42 codes, and Medicare paid $949K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-16.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 33,846 | 41 | $8.98 | $304K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 17,891 | 186 | $0.10 | $1,778 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 2,565 | 154 | $0.22 | $553 |
| 99214 Office E&M - Established | Office | 1,170 | 421 | $78.69 | $92K |
| J7325 Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | Office | 816 | 11 | $6.09 | $4,969 |
| J0897 Injection, denosumab, 1 mg | Office | 780 | 13 | $21.46 | $17K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 731 | 76 | $0.74 | $543 |
| 99213 Office E&M - Established | Office | 526 | 265 | $56.03 | $29K |
| 20610 Joint Injection | Office | 356 | 164 | $43.85 | $16K |
| 96413 Chemotherapy Administration | Office | 330 | 60 | $81.51 | $27K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 319 | 60 | $0.52 | $165 |
| 36415 Venipuncture Blood Collection | Office | 292 | 60 | $8.59 | $2,510 |
| 20552 Musculoskeletal | Office | 242 | 118 | $29.18 | $7,062 |
| 20605 Joint Injection | Office | 95 | 57 | $36.23 | $3,442 |
| J1040 Injection, methylprednisolone acetate, 80 mg | Office | 80 | 65 | $6.53 | $522 |
By year: 2022 $1.1M for 96,486 services; 2023 $1.1M for 105,381 services; 2024 $949K for 115,355 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 292 | 60 | $8.59 | $2,510 |
Medicare prescription drug claims, 2024
In 2024, the drug Ladislas Lazaro IV prescribed most often to Medicare patients was Tramadol Hcl, with 339 prescriptions and refills. In total Ladislas Lazaro IV wrote 3,374 Medicare prescriptions that cost $961K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tramadol Hcl Generic | 339 | 396 | 65 | $2,916 |
| Prednisone Generic | 328 | 661 | 92 | $2,503 |
| Methotrexate Methotrexate Sodium | 247 | 553 | 64 | $6,127 |
| Alprazolam Generic | 191 | 226 | 29 | $1,051 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 187 | 188 | 31 | $4,910 |
| Methylprednisolone Generic | 185 | 314 | 88 | $4,113 |
| Trazodone Hcl Generic | 138 | 329 | 45 | $1,590 |
| Celecoxib Generic | 137 | 325 | 44 | $5,925 |
| Gabapentin Generic | 136 | 290 | 37 | $2,084 |
| Meloxicam Generic | 109 | 289 | 38 | $931 |
| Pregabalin Generic | 103 | 233 | 33 | $3,678 |
| Hydroxychloroquine Sulfate Generic | 97 | 208 | 29 | $4,686 |
| Mycophenolate Mofetil Generic | 84 | 153 | 18 | $8,830 |
| Leflunomide Generic | 74 | 204 | 26 | $5,213 |
| Duloxetine Hcl Generic | 65 | 177 | 18 | $2,034 |
Brand drugs: 195 claims; generic drugs: 3,179 claims; opioid claims: 549.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ladislas Lazaro IV $24K ($24K in general payments such as food, travel and fees) from 16 companies. The largest payer was Amgen Inc. with $22K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 43 | $22K |
| Abbvie Inc. ABBV | 33 | $608 |
| Janssen Biotech, Inc. JNJ | 14 | $338 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $224 |
| GlaxoSmithKline, LLC. GSK | 11 | $212 |
| UCB, Inc. UCB.BR | 7 | $158 |
| Mallinckrodt Hospital Products Inc. | 3 | $147 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $95.03 |
| ANI Pharmaceuticals, Inc. ANIP | 3 | $68.18 |
| Fresenius Kabi USA, LLC | 3 | $64.23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.